T-DM1 received approval by the FDA in early 2013 to treat recurrent and refractory HER2-positive metastatic or locally advanced breast cancer previously treated with trastuzumab and a taxane [51, 52]. The gene discussed is ERBB2; the disease is breast carcinoma.